Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4219544 | 0.87 | SMN1; SMN2 (0.40) | SMN1; SMN2NFE2L2CA12CA1CA2 | |
| SCHEMBL439080 | 0.81 | MAPT (0.40) | SMN1; SMN2NPC1KDM4ELMNAHPGD | |
| SCHEMBL97524 | 0.80 | CA1 (0.55) | SMN1; SMN2CA12CA1CA2CA14 | |
| SCHEMBL6208942 | 0.79 | TSHR (0.40) | SMN1; SMN2CA1CA2NPC1KDM4E | |
| SCHEMBL6196015 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2NFE2L2CA12CA1CA2 | |
| SCHEMBL18245223 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2NFE2L2CA12CA1CA2 | |
| SCHEMBL7883890 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2NFE2L2CA12CA1CA2 | |
| SCHEMBL11511313 | 0.79 | CA1 (0.42) | SMN1; SMN2CA12CA1CA2CA14 | |
| SCHEMBL338999 | 0.79 | POLB (0.50) | SMN1; SMN2CA12CA1CA2CA14 | |
| SCHEMBL2733872 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2NFE2L2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596716-B2 | Compounds and matrices for use in bone growth and repair | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2023-03-07 | — | — | US | claimed |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2021-05-13 | — | — | US | claimed |
| US-9682954-B2 | Phenanthridine derivatives, preparation methods and uses thereof | KUNMING INSTITUTE OF BOTANY, THE CHINESE ACADEMY OF SCIENCES (CN) | 2017-06-20 | — | — | US | claimed |
| EP-3038621-A2 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | Human Biomolecular Research Institute (US) | 2016-07-06 | — | — | EP | claimed |
| CN-103145617-B | Phenanthridines analog derivative and pharmaceutical composition thereof and its preparation method and application | KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-04-06 | — | — | CN | claimed |
| US-20160083364-A1 | Phenanthridine Derivatives, Preparation Methods and Uses Thereof | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2016-03-24 | — | — | US | claimed |
| US-20160038641-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2016-02-11 | — | — | US | claimed |
| US-9249116-B2 | Enzyme-activating compounds and compositions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-02-02 | — | — | US | claimed |
| US-20150210659-A1 | PARTICULATE DRUG DELIVERY METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-07-30 | — | — | US | claimed |
| WO-2014146039-A2 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2014-09-18 | — | — | WO | claimed |
| EP-0977989-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2000-02-09 | — | — | EP | claimed |
| US-5989462-A | PHOTOPOLYMERIZING WITHIN A MOLD A PLASTIC LENS FORMING LIQUID MIXTURE COMPRISING MONOMERS, LIGHT ABSORBING COMPOUND, PHOTOINITIATOR AND CO-INITIATOR WHEREBY THE CO-INITIATOR ACTIVATED BY PHOTOINITIATOR CAUSES COMPLETE CURE | Q2100, INC. (US) | 1999-11-23 | — | — | US | claimed |
| WO-1999006887-A1 | METHOD AND COMPOSITION FOR PRODUCING ACTIVATING LIGHT ABSORBING LENSES | Q2100, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998034111-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| US-4916128-A | Thiadiazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-04-10 | — | — | US | claimed |
| US-4914093-A | CARDIOVASCULAR DISORDERS | SANKYO COMPANY LIMITED (JP) | 1990-04-03 | — | — | US | claimed |
| US-4442305-A | FOR USE IN CITRO OR IN VIVO | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1984-04-10 | — | — | US | claimed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | claimed |
| US-4053608-A | 3-NITROPYRIDINE CARBOXAMIDES, POULTRY FEED | SANKYO COMPANY LIMITED (JA) | 1977-10-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596716-B2 | Compounds and matrices for use in bone growth and repair | BMP2, BMP4, BMP6 | SMN1; SMN2 3759/4885NFE2L2 1181/4885CA12 1944/4885 |
| US-20160083364-A1 | Phenanthridine Derivatives, Preparation Methods and Uses Thereof | CTNNB1, WNT3A, WNT1 | SMN1; SMN2 4646/4885NFE2L2 252/4885CA12 3732/4885 |
| US-20150210659-A1 | PARTICULATE DRUG DELIVERY METHODS | CASP3, BAX, CASP5 | SMN1; SMN2 3012/4885NFE2L2 579/4885CA12 1189/4885 |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | BMP2, BMP4, BMP6 | SMN1; SMN2 3759/4885NFE2L2 1181/4885CA12 1944/4885 |
| US-20160038641-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | BMP2, BMP4, BMP6 | SMN1; SMN2 3375/4885NFE2L2 1486/4885CA12 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.